近日，三生制药发布公告称，公司建议将附属公司蔓迪股份分拆并于联交所主板独立上市。建议分拆 （倘进行）预计将通过本公司按董事会为确定股东权利而厘定的记录日期，根据股东各自于本公司的持 股比例，以实物分派方式向股东分派其持有的蔓迪全部股份及蔓迪新股的全球发售，包括香港公开发售 及国际发售。 2025年11月20日，蔓迪已向联交所递交申请，以实物分派本公司持有的蔓迪全部股份及全球发售蔓迪新 股的方式，批准蔓迪股份在联交所主板上市。蔓迪上市文件的经编纂申请版本（「申请版本」）刊载于 联交所网站以供阅览及下载。 蔓迪是一家在开曼群岛注册成立的获豁免有限公司，且为三生制药公司的附属公司。于公告日期，蔓迪 由本公司、英泰管理有限公司、MandiGroupLimited、GLWecanInvestmentIVL.P.及阿里健康（香港）科 技有限公司实益拥有约87.16%、3.38%、2.80%、4.00%及2.65%的权益。 药师帮：第三季度收入同比增长15%，致力于推出高质量自有品牌产品 近日，药师帮发布公告称，截至2025年9月30日止三个月，公司连同其附属公司及综合联属实体的收入 同比增长15%。这一增长超过了2025 ...

今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科技发展公司等机构的上亿 元投资。 据了解，本轮融资将用于医疗大模型的持续迭代、核心产品矩阵的拓展升级以及重点区域市场的布局深 化。 来源：猎云网 近日，智能医疗解决方案提供商商汤医疗完成数亿元新一轮战略融资，本轮投资方包括联想创投、联创 资本、九弦资本、申冉投资等。 多模态医学图像基础模型群，涵盖医学图像、文本、生物信息等数据模态；可针对放射、病理等不同图 像模态，实现检测、分割、分类等任务，并支持小样本、弱标注的高效率模型训练，以突破医疗"长尾 问题"数据样本少、标注难度高的瓶颈。 商汤医疗CEO张少霆表示，未来将持续引入具备生态协同能力的产业合作方、财务投资人，共同构建 AI医疗生态，加速医疗行业智慧化升级。 据悉，商汤医疗构建了医疗健康大语言模型"大医"、多模态医学图像基础模型群，以"通专融合"为技术 路径，推动"未来智慧医院"建设。 "大医"模型，以千亿参数规模的商汤日日新"商量"大语言模型为基模，利用海量高质量医学知识数据训 练而成，具备感知、推理及规划能力。该模型目前可覆盖智能自诊、用药咨询、影像报告结构化、临床 辅助决策等多个细 ...

Group 1 - SenseTime Medical has completed a strategic financing round of several hundred million yuan, with investors including Lenovo Ventures, Lianchuang Capital, and others, and is currently initiating Series A financing with a post-investment valuation exceeding 3 billion yuan [1] - The company is leveraging AI technology to promote the construction of "future smart hospitals," with core technology engines including the medical health large language model "Dai Yi" and a multi-modal medical image foundational model group [1] - The "Dai Yi" model, based on SenseTime's large language model with hundreds of billions of parameters, is capable of covering various medical scenarios such as intelligent self-diagnosis, medication consultation, and clinical decision support [1] Group 2 - CEO Zhang Shaoting emphasizes that while pure technology can provide a first-mover advantage in the competitive medical AI industry, a rich product matrix and capital-supported industrial ecosystem are harder to replicate [2] - Since 2018, the company has adopted a platform-based strategy to empower comprehensive hospital diagnosis and treatment, resulting in applications across clinical diagnosis, intelligent decision-making, patient services, and medical research [2] - To avoid price wars in standardized software, SenseTime Medical has established a dual middle platform system for intelligent agent development and model application production, creating a differentiated advantage [2] Group 3 - The company aims to continuously attract industry partners and financial investors with ecological synergy capabilities to accelerate the intelligent upgrade of the medical industry [3]